Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

Core Insights - Rakovina Therapeutics is advancing its AI-derived PARP-1 inhibitor program, showcasing progress at the 2025 Society for Neuro-Oncology Annual Meeting [1][5] - The company is utilizing AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates that penetrate the central nervous system (CNS) [2][4] Research and Development - A scientific poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors" was presented, highlighting collaboration with the Vancouver Prostate Centre and the University of British Columbia [2] - The research employs Deep Docking™ and generative-AI computational approaches to screen large chemical libraries for compounds with selective inhibition of PARP1 and favorable drug-like properties [3][4] Results and Data - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and promising in vitro metabolic stability and pharmacokinetic profiles [4] - The presentation included comparisons of ADME and pharmacokinetic data from synthesized compounds against existing PARP inhibitors and next-generation benchmarks [4] Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]